Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...

Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...

Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently convert ...

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...

For the most part, Aussie investors chose the sidelines today ahead of a major US jobs report due early tomorrow morning our ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on ...

The novel method utilizes sporopollenin, a naturally abundant waste product, as a scaffold for the growth of copper oxide ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...